217 related articles for article (PubMed ID: 36622841)
1. Radiotheranostics in oncology: Making precision medicine possible.
Aboagye EO; Barwick TD; Haberkorn U
CA Cancer J Clin; 2023; 73(3):255-274. PubMed ID: 36622841
[TBL] [Abstract][Full Text] [Related]
2. Advances in Radioligand Theranostics in Oncology.
Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
[TBL] [Abstract][Full Text] [Related]
3. Next generation radiotheranostics promoting precision medicine.
Pomykala KL; Hadaschik BA; Sartor O; Gillessen S; Sweeney CJ; Maughan T; Hofman MS; Herrmann K
Ann Oncol; 2023 Jun; 34(6):507-519. PubMed ID: 36924989
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
5. Theranostics in oncology: What radiologists want to know.
Ferdinandus J; Fendler WP; Morigi JJ; Fanti S
Eur J Radiol; 2021 Sep; 142():109875. PubMed ID: 34391057
[TBL] [Abstract][Full Text] [Related]
6. Radiotheranostics in oncology: current challenges and emerging opportunities.
Bodei L; Herrmann K; Schöder H; Scott AM; Lewis JS
Nat Rev Clin Oncol; 2022 Aug; 19(8):534-550. PubMed ID: 35725926
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacology of Radiotheranostics in Oncology.
Te Beek ET; Burggraaf J; Teunissen JJM; Vriens D
Clin Pharmacol Ther; 2023 Feb; 113(2):260-274. PubMed ID: 35373336
[TBL] [Abstract][Full Text] [Related]
8. Radiotheranostics in advanced prostate cancer: Current and future directions.
Jia AY; Kiess AP; Li Q; Antonarakis ES
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):11-21. PubMed ID: 37069330
[TBL] [Abstract][Full Text] [Related]
9. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Radiotheranostics in Cancer Diagnosis and Management.
Jadvar H; Chen X; Cai W; Mahmood U
Radiology; 2018 Feb; 286(2):388-400. PubMed ID: 29356634
[TBL] [Abstract][Full Text] [Related]
12. Development of Diagnostic and Therapeutic Probes with Controlled Pharmacokinetics for Use in Radiotheranostics.
Ogawa K
Chem Pharm Bull (Tokyo); 2019; 67(9):897-903. PubMed ID: 31474726
[TBL] [Abstract][Full Text] [Related]
13. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan H; Iagaru A; Aparici CM
Nanotheranostics; 2022; 6(1):103-117. PubMed ID: 34976584
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
15. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
[TBL] [Abstract][Full Text] [Related]
16. The application of theranostics in different stages of prostate cancer.
Alghazo O; Eapen R; Koschel S; Cumberbatch M; Buteau J; Loh R; Lawrentschuk N; Murphy DG
Future Oncol; 2021 Sep; 17(27):3637-3644. PubMed ID: 34227404
[TBL] [Abstract][Full Text] [Related]
17. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen.
Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP
Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048
[TBL] [Abstract][Full Text] [Related]
18. Theranostics of Metastatic Prostate Cancer Applying
Mirzaei S; Mohammed F; Zandieh S
Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
[TBL] [Abstract][Full Text] [Related]
19. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach.
Filippi L; Urso L; Bianconi F; Palumbo B; Marzola MC; Evangelista L; Schillaci O
Expert Rev Mol Diagn; 2023 Mar; 23(3):243-255. PubMed ID: 36927210
[TBL] [Abstract][Full Text] [Related]
20. An Impressive Approach in Nuclear Medicine: Theranostics.
Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
